Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... downstream of EPO action. Novel transforming growth factor (TGF)-β superfamily inhibitors sotatercept and luspatercept ...

    Research Article last updated 10/23/2017 - 11:08am.

  2. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... downstream of EPO action. Novel transforming growth factor (TGF)-β superfamily inhibitors sotatercept and luspatercept ...

    Research Article last updated 10/02/2017 - 10:10am.

  3. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

    ... is a novel fusion protein that blocks transforming growth factor beta (TGF β) superfamily inhibitors of erythropoiesis, giving rise ...

    Research Article last updated 09/18/2017 - 1:38pm.

  4. Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

    ... at 3 and 6 months, respectively. While additional growth factor interventions led to faster count recovery, there were no ...

    Research Article last updated 09/13/2017 - 7:40am.

  5. Promising trial results for lower-risk MDS drug

    ... is a novel fusion protein that blocks transforming growth factor beta (TGF β) superfamily inhibitors of erythropoiesis, giving rise ...

    Article last updated 09/07/2017 - 11:08am.

  6. Making Progress for Myelodysplastic Syndromes

    ... treatment because in CMML they have oversensitivity to a growth factor called GM-CSF, where Jakafi will target. We conducted the first ...

    Article last updated 07/26/2017 - 10:25am.

  7. High levels of vascular endothelial growth factor protein expression are associated with an increased risk of transfusion dependence in myelodysplastic syndromes

    ... the prognostic significance of vascular endothelial growth factor (VEGF) protein expression in 79 bone marrow biopsy specimens ...

    Research Article last updated 03/05/2013 - 9:11am.

  8. Treatment of low-risk myelodysplastic syndromes

    ... neutropenia is targeted symptomatically with growth factor supportive care , the immunosuppressive treatments are ...

    Research Article last updated 01/26/2017 - 10:42am.

  9. Growth Factors

    ... Red Cell Growth Factor Red cell growth factor is ...

    Topic section last updated 04/06/2016 - 12:37pm.

  10. Paroxysmal Nocturnal Hemoglobinuria (PNH)

    ... of mature PNH red blood cells. Some doctors believe this growth happens because people with PNH have bone marrow that is weaker than ... Having aplastic anemia is the only known risk factor for developing PNH. More than 10 out of every 100 people with aplastic ...

    Page last updated 09/30/2017 - 11:34am.